Lead Product(s) : Clevudine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : L-FMAU (Clevudine) is a synthetic β-L nucleoside analogue introduced from Yale University and HebaBiz Biotech obtained its exclusive license for anti-hepatitis B virus in Greater China. L-FMAU as a new generation best-in-class anti-HBV new drug.
Product Name : L-FMAU
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 15, 2021
Lead Product(s) : Clevudine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Clevudine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Leukavir, an Antiviral Agent for Bukwang Pharm, Confirmed the Effect on New Coronavirus
Details : Levovir (clevudine) was found to be effective on virus isolated from the specimens of Korean Coronavirus Infectious Disease-19 (COVID-19) patients, similar to calletra used for the treatment of COVID-19 in vitro.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 03, 2020
Lead Product(s) : Clevudine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable